AMEX:
CTT
 
| FINANCIAL HIGHLIGHTS |
| (in Millions; FY ends 7/31) |
| |
1999 |
1998 |
| Revenue |
$3.64 |
$2.61 |
| Retained royalties |
$3.46 |
$2.40 |
| Operating expenses |
$3.22 |
$3.99 |
| L/T debt |
$0.00 |
$0.00 |
| EPS $/share |
$ 0.49 |
($ .021) |
DIRECT INQUIRIES TO:
Competitive Technologies, Inc.
1960 Bronson Road
P.O. Box 340
Fairfield, CT 06430
Voice: (203) 255-6044
Fax: (203) 254-1102
CTT@CompetitiveTech.net
or
Johnnie Johnson
Strategic IR
800 Third Avenue, Suite 3700
New York, NY 10022
Voice: (212) 754-6565
Fax: (212) 754-4333
Jdjohnson@strategic-ir.com
Please visit our website:
http://www.competitivetech.net
|
WHAT’S NEW
- CTT reported another success with its licensing agreement with Matsushita Electronics
Corporation for CTT’s high power laser diode technology. CTT also reported a 36%
increase in revenue compared to the same quarter of the previous fiscal year.
- CTT has also recently licensed four exciting technologies which are currently generating
revenues and have the potential to provide solutions in billion dollar markets.
These four technologies include:
Homocysteine Assays.
CTT holds a patent
on the performance of assays for homocysteine (Hcy). Elevated levels of homocysteine have
been identified as a risk factor for cardiovascular disease.
Plasma Display Panel Energy
Recovery Circuit. This
technology provides a more cost efficient way to manufacture and operate large (42"
and larger) screen televisions which are only 3 ½ inches thick. This circuit also allows
manufacturers to comply with current FCC RF emission requirements.
Public Key Encryption.
This fully scalable, low power
method of encrypting digital transmissions is ideal for use on the Internet, e-commerce,
telecommunications and smart-cards.
Laser Diode DVD-RAM.
The laser diode represented by
CTT offers an enhanced, more durable, and more reliable laser needed for DVD-RAM drives
and other optical storage devices.
- Additionally, CTT currently has licensed four technologies which are in FDA trials or
pre-clinical studies for the treatment of Hepatitis C, Erectile Dysfunction,
Cancer and Herpes.
THE FUTURE
- CTT continues to increase revenues and expects to do so for the foreseeable future as a
result of recently completed license agreements and other equity investments.
 CTT has
refocused the Company to develop exciting technologies with a high probability of
generating significant revenues.
- CTT has embarked on a new investor relations and public relations program. CTT
believes its growth potential will benefit its shareholders and that by gaining exposure
to the investment community, CTT will increase the value of their share holdings.
- As CTT continues to grow its established life sciences portfolio, it is focused on
increasing its digital technologies portfolio. Unlike the life sciences technologies,
digital technologies have a much shorter development life cycle and can produce revenues
much more quickly.
- 1999 revenues were at an all time high and expenses
were lower than revenues, yielding operating income.
In the first quarter of fiscal 2000, CTT revenues of $570,827 increased by 36% over the
prior year first quarter and the net loss of $141,066, which was $174, 832 (55%) lower
than the first quarter of fiscal 1999, generated net income of $409,000, $0.07 per share,
and operating income of $433,000. CTT has no long-term
debt, net cash and investments of more than $5,500,000, and net operating loss tax
carryforwards of approximately $16,000,000.
OUR BUSINESS
- · Corporate Overview
-
Competitive Technologies, Inc. (CTT) is a world
leader in technology commercialization. CTT’s focus is to identify,
patent, license, and commercialize technologies from corporations, universities, and early
start-ups. With experience in managing, developing and commercializing technology, CTT is
able to identify promising technologies and shepherd them through development to provide
solutions to today’s business and health problems.
· Objective
CTT’s objective is to optimize and realize the potential value of its
client’s technology portfolios. CTT provides the services of licensing and
enforcing intellectual property rights, structuring business arrangements (e.g. forming
joint ventures and start-up companies), and obtaining investment financing. CTT’s
world class team of professionals with diverse technical, legal, intellectual property,
financial, market and business expertise provides clients a complete range of technology
commercialization services.
· Generating Revenue
CTT’s team constantly searches for new and emerging technologies to address
problems of today and tomorrow. CTT realizes revenue in various forms from up-front
payments, running royalties, sales and equity by shepherding technologies
through development and matching them with strategic partners or licensees.
· Focus
CTT provides services in three sectors: Life Sciences (including
pharmaceuticals, biomedical devices, biotechnology and clinical diagnostics), Physical
Sciences (including materials, manufacturing and environmental) and Digital
Technologies (including Internet services, telecommunications, and digital
entertainment). The life cycles of commercializing technologies in these fields are very
different. By diversifying its portfolio of technologies, CTT maximizes the probability of
generating near-and long-term revenue. Innovations with shorter times to market provide
necessary revenues to develop the longer-term opportunities.
· Clients and Customers
CTT currently has more than 50 clients including such renowned research companies as
Lucent Technologies and Monsanto Co., as well as educational institutions like the
University of Illinois and the University of Colorado. Of the more than 80 customers now
using CTT licensed technologies, a few representative customers include major electronic
companies like SONY, Mitsubishi Electric Corp. and Matsushita Electric Industrial and
major biological companies like Abbott Laboratories and Roche Molecular Systems, Inc.
· Successes
CTT has successfully licensed more than 450 technologies to over 300 individual
organizations. Since its inception, these licenses have generated approximately $27
million dollars in retained royalties to CTT. Some of these successes include plasma
display monitors, vitamin B12 assay, gene sequencing machine, gallium arsenide
semiconductors, and a unique encryption, decryption, and authentication algorithm.
|
